Abstract P1-01-01: Analytical validation of a standardized scoring protocol for Ki67: Phase-3 of an international multicenter collaboration
暂无分享,去创建一个
John M S Bartlett | Indu Arun | Mitch Dowsett | Lila Zabaglo | Sharon Nofech-Mozes | Lisa M McShane | Andrew Dodson | Susan Fineberg | Dongxia Gao | Carolina Gutierrez | Zuzana Kos | Takuya Moriya | Daniel F Hayes | Roberto Salgado | A. Gown | S. Leung | T. Nielsen | M. Dowsett | L. McShane | S. Badve | G. Viale | J. Bartlett | F. Penault-Llorca | Z. Kos | R. Salgado | S. Fineberg | D. Hayes | C. Osborne | L. Zabaglo | I. Arun | M. Lin | D. Grabau | M. Mastropasqua | D. Gao | J. Hugh | T. Piper | R. Enos | S. Nofech-Mozes | A. Dodson | Samuel C Y Leung | Torsten O Nielsen | Sunil S Badve | Anita L Bane | Signe Borgquist | Martin C Chang | Rebecca A Enos | Cornelia M Focke | Allen M Gown | Dorthe Grabau | Judith C Hugh | Anne-Vibeke Lænkholm | Ming-Gang Lin | Mauro G Mastropasqua | C Kent Osborne | Frédérique M Penault-Llorca | Tammy Piper | Takashi Sakatani | Jane Starczynski | Giuseppe Viale | J. Starczynski | A. Lænkholm | T. Moriya | T. Sakatani | C. Gutierrez | S. Borgquist | S. Leung | A. Bane | D. Hayes | J. Bartlett | A. Bane | S. Badve | J. Hugh | C. Focke | Martin C. Chang | C. Osborne | Daniel F. Hayes | T. Piper | Lisa M. McShane | Mitchell Dowsett | J. Bartlett | SS Badve | S. Borgquist | Martin C. Chang | A. Dodson | RA Enos | D. Gao | AM Gown | C. Gutierrez | Z. Kos | M-G Lin | MG Mastropasqua | T. Moriya | S. Nofech-Mozes | CK Osborne | F. Penault-Llorca | Rodrigo Salgado | G. Viale | T. O. Nielsen
[1] Pierre-Marie Martin,et al. Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review , 2011, Breast Cancer Research and Treatment.
[2] J. R. Landis,et al. The measurement of observer agreement for categorical data. , 1977, Biometrics.
[3] C Caldas,et al. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. , 2008, Breast.
[4] P. Neven,et al. Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer : BIG 198 , 2007 .
[5] J. Cuzick,et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] John M S Bartlett,et al. An international study to increase concordance in Ki67 scoring , 2015, Modern Pathology.
[7] A. Luini,et al. Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes , 2014, Breast Cancer Research.
[8] A. Goldhirsch,et al. High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer. , 2014, Breast.
[9] Carsten Denkert,et al. Strategies for developing Ki67 as a useful biomarker in breast cancer. , 2015, Breast.
[10] H Tesch,et al. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[12] John M S Bartlett,et al. An international Ki67 reproducibility study. , 2013, Journal of the National Cancer Institute.
[13] P. Neven,et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] R. Gelber,et al. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. , 2008, Journal of the National Cancer Institute.
[15] K. Gelmon,et al. Ki67 in breast cancer: prognostic and predictive potential. , 2010, The Lancet. Oncology.
[16] M Buyse,et al. St Gallen International Expert Consensus on the primary therapy of early breast cancer: an invaluable tool for physicians and scientists. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] M. Ling,et al. Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score , 2015, Modern Pathology.
[18] C. Sotiriou,et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients , 2007, British Journal of Cancer.
[19] M. Dowsett,et al. Comparative validation of the SP6 antibody to Ki67 in breast cancer , 2010, Journal of Clinical Pathology.
[20] M. Desouki,et al. The role of immunohistochemistry in the evaluation of gynecologic pathology part 2: a comparative study between two academic institutes. , 2015, Annals of diagnostic pathology.
[21] S. Barni,et al. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients , 2015, Breast Cancer Research and Treatment.
[22] Minfeng Chen,et al. The Prognostic Role of Ki-67/MIB-1 in Upper Urinary-Tract Urothelial Carcinomas: A Systematic Review and Meta-Analysis. , 2015, Journal of endourology.
[23] F. Zeman,et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry , 2013, Breast Cancer Research and Treatment.
[24] R. Gelber,et al. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] M. Ferrarini,et al. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients. , 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[26] A. Gown,et al. Routine pathologic parameters can predict Oncotype DXTM recurrence scores in subsets of ER positive patients: who does not always need testing? , 2011, Breast Cancer Research and Treatment.
[27] Jack Cuzick,et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.